MedTrace Logo

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

NCT06279130 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2026-03-05

No results posted yet for this study

Summary

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

Conditions

  • Resectable MMR-deficient Solid Tumors
  • Resectable MMR-proficient Solid Tumors

Interventions

DRUG

botensilimab

Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

DRUG

balstilimab

Anti programmed cell death protein-1 (anti-PD1)

DRUG

FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

5-Fluorouracil (2400mg/m2), leucovorin (200mg/m2), oxaliplatin (85mg/m2), docetaxel (50mg/m2).

Sponsors & Collaborators

  • Agenus Inc.

    collaborator INDUSTRY

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Myriam Chalabi, MD PhD · The Netherlands Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2029-01-29
Completion
2034-01-29

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06279130 on ClinicalTrials.gov